Temperature Management Devices Are Hot

Doctors have long theorized that being able to precisely warm (hyperthermia) and cool (hypothermia) patients, depending on their conditions and surroundings, would be beneficial in a variety of neurological and cardiovascular procedures. This has given rise to a group of medical device companies formed in the mid-to-late 1990s dedicated to developing temperature management systems. The big question has ben whether clinical data would validate the bets these companies made in this space. Early clinical data released recently has been positive, and large companies are interested in this area, sparking the first major temperature management deal.

One person was trapped in the snow; another fell into an icy lake; the tales have been told of people suffering some type of neurological or cardiac event in which damage was minimized because of exposure to extreme cold. Doctors have long theorized that being able to precisely warm (hyperthermia) and cool (hypothermia) patients, depending on their conditions and surroundings, would be beneficial in a variety of neurological and cardiovascular procedures. Between 1996 and 1998 these hypotheses gave rise to a group of medical device start-ups dedicated to developing temperature management systems, including Medivance Inc. , Cardeon Corp. , Radiant Medical Inc. , and Innercool Therapies Inc. Other companies operating in this space include Alsius Inc. and Seacoast Technologies Corp. (See "Medical Device's Ice Age," IN VIVO, January 2001 Also see "Medical Device's Ice Age" - In Vivo, 1 January, 2001.; "Medivance: Climate Control for the Body," IN VIVO, July 2001 Also see "Medivance: Climate Control for the Body" - In Vivo, 1 July, 2001.;"Innercool Therapies Inc.," START-UP, January 2000 Also see "Innercool Therapies Inc." - Medtech Insight, 1 January, 2000.;"Radiant Medical Inc.," START-UP, May 2000 Also see "Radiant Medical Inc." - Medtech Insight, 1 May, 2000.;"Cardeon Corp.," START-UP, October 2000 Also see "Cardeon Corp." - Medtech Insight, 1 October, 2000..)

The big question in temperature management has been whether clinical data would validate the bets these companies made in this space. Since these therapies are used in high-risk patients, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By 

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By 

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By 

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.

More from R&D

ConcertAI Launches Generative AI-Powered Precision Suite

 

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Handheld Diagnostics: A Resurging Category That is Here to Stay

 

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.